Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

The oxytocin system – which helps release breast milk and strengthens the bond between mother and baby – may be affected ...

The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.

KLOXXADO ® delivers 8 mg of naloxone hydrochloride per spray in a ready to use nasal spray to reverse the effects of opioid overdose.

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

The oxytocin system -- which helps release breast milk and strengthens the bond between mother and baby -- may be affected during breastfeeding in mothers experiencing postnatal depression.

Breastfeeding mothers with postnatal depression show disruptions in oxytocin systems, impacting bonding and milk release.

The oxytocin system - which helps release breast milk and strengthens the bond between mother and baby - may be affected ...

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates ...